Banking & Finance  December 2, 2016

Boulder-based Biodesix raises another $5.1 million

BOULDER — Local diagnostic test-maker Biodesix Inc. has pulled in another new chunk of funding as the company continues to grow its Veristrat and other products.

According to a regulatory filing made this week, the company has raised about $5.1 million through the issuance of new convertible notes. The filing noted a total offering of $15.7 million, meaning more cash could be on the way.

Biodesix CEO David Brunel couldn’t be reached for comment Friday.

SPONSORED CONTENT

Business Cares: March 2024

WomenGive, a program of United Way of Larimer County, was started in Larimer County in 2006 as an opportunity for women in our community to come together to help other women.

Biodesix, which is headquartered at 2970 Wilderness Place, makes a line of blood tests that are focused on identifying which cancer patients could best benefit from various cancer drugs, because most cancer drugs work only on specific sets of the population.

In February, the company raised a Series F funding round of $17.8 million, and then tacked on another $6.1 million of equity funding in July. The company has now raised well more than $100 million since its founding in 2005.

BOULDER — Local diagnostic test-maker Biodesix Inc. has pulled in another new chunk of funding as the company continues to grow its Veristrat and other products.

According to a regulatory filing made this week, the company has raised about $5.1 million through the issuance of new convertible notes. The filing noted a total offering of $15.7 million, meaning more cash could be on the way.

Biodesix CEO David Brunel couldn’t be reached for comment Friday.

Biodesix, which is headquartered at 2970 Wilderness Place, makes a line of blood tests that are focused on identifying which…

Sign up for BizWest Daily Alerts